Jagsonpal Pharma Peer Comparison
NSE: JAGSNPHARM | BSE: 507789
₹220.29
₹8.53
(4.03%)
As on 26-Oct-2026 11:29IST
Market cap
₹1,427 Cr
Revenue (TTM)
₹294 Cr
P/E Ratio
31.4
P/B Ratio
6.2
Div. Yield
2.5 %
Edit
| Jagsonpal Pharma | Caplin Point Lab | Shilpa Medicare | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
1,427 | 17,504 | 17,557 | 16,963 | 15,209 |
Revenue (₹ Cr) |
294 | 2,287 | 1,682 | 2,570 | 3,230 |
Net Profit (₹ Cr) |
45.48 | 678.07 | 273.51 | 735.15 | 666.92 |
Net Margin (%) |
14.87 | 28.10 | 16.19 | 26.88 | 20.60 |
RoE (%) |
17.79 | 19.73 | 11.15 | 19.16 | 18.75 |
Price to Earnings |
31.38 | 26.31 | 59.05 | 23.07 | 23.62 |
Price-To-Book |
6.20 | 4.77 | 6.54 | 3.85 | 3.77 |
Income Statement (₹ Cr)
| Jagsonpal Pharma | Caplin Point Lab | Shilpa Medicare | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Operating Revenue
|
293.85 | 2,287.33 | 1,682.47 | 2,569.77 | 3,229.67 |
|
Total Income
|
305.85 | 2,413.29 | 1,689.83 | 2,735.39 | 3,237.12 |
|
Total Expenditure
|
232.74 | 1,490.75 | 1,203.91 | 1,628.14 | 2,090.06 |
|
EBITDA
|
61.10 | 796.58 | 478.55 | 941.63 | 1,139.61 |
|
Depreciation
|
9.23 | 78.10 | 126.01 | 57.58 | 281.06 |
|
EBIT
|
51.87 | 718.48 | 352.55 | 884.05 | 858.55 |
|
Interest
|
1.03 | 0.88 | 52.11 | 7.69 | 190.64 |
|
Other Income
|
12.00 | 125.96 | 7.37 | 165.62 | 7.45 |
|
Exceptional Items
|
-2.08 | 0.00 | 12.16 | -49.16 | -17.24 |
|
Profit before Tax
|
60.77 | 843.56 | 319.96 | 992.82 | 658.12 |
|
Provision for Tax
|
15.29 | 165.49 | 46.45 | 257.67 | -8.80 |
|
Profit after Tax
|
45.48 | 678.07 | 273.51 | 735.15 | 666.92 |
Liabilities (₹ Cr)
| Jagsonpal Pharma | Caplin Point Lab | Shilpa Medicare | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
276.17 | 3,586.42 | 2,591.20 | 4,202.90 | 3,902.67 |
|
Minority Interest
|
0.00 | -12.71 | 0.00 | 0.00 | -21.81 |
|
Non-Current Liabilities
|
12.21 | 28.74 | 266.35 | 91.50 | 1,392.75 |
|
Current Liabilities
|
28.30 | 385.94 | 848.06 | 627.48 | 2,077.10 |
|
Total Liabilities
|
329.30 | 4,037.51 | 3,705.61 | 4,921.88 | 7,246.72 |
Assets (₹ Cr)
| Jagsonpal Pharma | Caplin Point Lab | Shilpa Medicare | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
78.53 | 1,291.22 | 2,525.44 | 770.28 | 5,617.77 |
|
Current Assets
|
143.09 | 2,585.66 | 1,109.77 | 3,803.22 | 1,539.85 |
|
Total Assets
|
329.30 | 4,037.51 | 3,705.61 | 4,921.88 | 7,246.72 |
|
Total Debt*
|
0.00 | 0.57 | 657.97 | 2.50 | 2,309.68 |
|
Net Current Assets
|
114.79 | 2,199.72 | 261.71 | 3,175.74 | -537.25 |
|
Contingent Liabilities
|
22.34 | 17.53 | 160.01 | 370.49 | 51.57 |
Cashflow (₹ Cr)
| Jagsonpal Pharma | Caplin Point Lab | Shilpa Medicare | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
46.81 | 523.24 | 342.18 | 967.57 | 537.99 |
|
Cash Flow from Investing Activities
|
-35.65 | -582.30 | -325.92 | -561.67 | -369.46 |
|
Cash from Financing Activities
|
-12.15 | -46.46 | 13.62 | -798.31 | -313.53 |
|
Net Cash Inflow / Outflow
|
-0.99 | -105.52 | 29.88 | -392.41 | -145.00 |
Ratios
Profitability Ratios
| Jagsonpal Pharma | Caplin Point Lab | Shilpa Medicare | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
|
ROCE (%)
|
22.69 | 24.97 | 11.43 | 23.39 | 14.47 |
|
ROE (%)
|
17.79 | 19.73 | 11.15 | 19.16 | 18.75 |
|
ROA (%)
|
15.29 | 18.69 | 7.80 | 14.95 | 9.26 |
|
EBIT Margin (%)
|
17.65 | 31.41 | 20.95 | 34.40 | 26.58 |
|
Net Margin (%)
|
14.87 | 28.10 | 16.19 | 26.88 | 20.60 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Jagsonpal Pharma | Caplin Point Lab | Shilpa Medicare | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
3.87 | 15.01 | 27.91 | 10.69 | 9.59 |
|
EBIT Growth (%)
|
13.66 | 18.45 | 58.32 | 24.14 | 16.84 |
|
Net Profit Growth (%)
|
-25.24 | 19.61 | 149.56 | -9.09 | 62.68 |
|
EPS Growth (%)
|
-20.48 | 17.73 | -3.57 | 14.40 | 67.41 |
|
Book Value Growth (%)
|
17.30 | 26.75 | 9.67 | -0.34 | 36.71 |
Valuation Ratios
| Jagsonpal Pharma | Caplin Point Lab | Shilpa Medicare | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Price / Earnings
|
29.93 | 25.39 | 60.21 | 21.41 | 23.05 |
|
Price / Book Value
|
6.07 | 4.60 | 6.28 | 3.75 | 3.78 |
|
Dividend Yield (%)
|
2.60 | 0.36 | 0.07 | 2.08 | 0.00 |
|
EV/EBITDA
|
21.15 | 19.94 | 36.54 | 14.24 | 15.33 |
|
Market Cap (₹ Cr)
|
1,234.49 | 11,439.22 | 6,819.66 | 21,592.90 | 17,980.08 |
Solvency Ratios
| Jagsonpal Pharma | Caplin Point Lab | Shilpa Medicare | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.00 | 0.07 | 0.00 | 0.24 |
|
Short term debt to equity ratio
|
-- | 0.00 | 0.16 | 0.00 | 0.12 |
|
Current Ratio
|
5.06 | 6.70 | 1.31 | 6.06 | 0.74 |
|
Quick Ratio
|
4.54 | 5.59 | 0.88 | 5.31 | 0.53 |
|
Interest Coverage
|
60.28 | 959.59 | 7.14 | 130.11 | 4.45 |
Operating Efficiency Ratios
| Jagsonpal Pharma | Caplin Point Lab | Shilpa Medicare | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
5.85 | 36.10 | 30.84 | 7.07 | 21.07 |
|
Asset Turnover
|
0.99 | 0.63 | 0.48 | 0.52 | 0.45 |
|
Receivable days
|
18.20 | 121.68 | 113.81 | 26.06 | 63.88 |
|
Inventory Days
|
17.89 | 63.83 | 84.76 | 65.95 | 43.27 |
|
Payable days
|
37.27 | 108.28 | 101.94 | 81.01 | 151.85 |
|
Cash Conversion Cycle
|
-1.18 | 77.23 | 96.62 | 11.00 | -44.70 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
